Factor VIII/von Willebrand factor - Octapharma

Drug Profile

Factor VIII/von Willebrand factor - Octapharma

Alternative Names: Human factor VWF/FVIII concentrate; Wilate

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease

Most Recent Events

  • 23 Mar 2017 Launched for Haemophilia A in Bulgaria, Estonia, Lithuania, Norway (IV) prior to March 2017
  • 23 Mar 2017 Launched for Von Willebrand's disease in Bulgaria, Czech Republic, Estonia, Hungary, Lithuania, Netherlands, Spain (IV) prior to March 2017
  • 22 Mar 2017 Registered for Haemophilia A in Bulgaria, Estonia, Greece, Latvia, Lithuania, Romania, Slovenia, Norway (IV) prior to March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top